BAT2206 is Bio-Thera Solutions’ third EC approvedproduct Guangzhou, China– August , 2024 – Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical companydeveloping a pipeline of innovative therapies and biosimilars, today announcedthat the EC has approved BAT2206 (ustekinum...
DetailsBio-Thera Solutions (SHA: 688177), a commercial-stage biopharmaceuticalcompany, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for BAT1706, a proposed biosimilar to Avastin ® (bevacizumab). The BLA seeks approval of BAT1706 for ...
GUANGZHOU, China and SAO PAULO, Brazil ---(Businesswire)--- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, today announced the company has reached a licensing agreement with Biomm S.A. for BAT 17 06, its be...
GUANGZHOU, China--( BUSINESS WIRE )--Bio-Thera Solutions (SHA: 688177), a commercial-stage biopharmaceuticalcompany, today announced that it has submitted the MAA for BAT1706, a proposed biosimilar to Avastin® (bevacizumab), to EMA. Bio-Thera seeks a commercial license for all approved indications ...